517 related articles for article (PubMed ID: 28606923)
1. Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells.
Jiang BY; Li YS; Guo WB; Zhang XC; Chen ZH; Su J; Zhong WZ; Yang XN; Yang JJ; Shao Y; Huang B; Liu YH; Zhou Q; Tu HY; Chen HJ; Wang Z; Xu CR; Wang BC; Wu SY; Gao CY; Zhang X; Wu YL
Clin Cancer Res; 2017 Sep; 23(18):5480-5488. PubMed ID: 28606923
[No Abstract] [Full Text] [Related]
2. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy.
Li YS; Jiang BY; Yang JJ; Zhang XC; Zhang Z; Ye JY; Zhong WZ; Tu HY; Chen HJ; Wang Z; Xu CR; Wang BC; Du HJ; Chuai S; Han-Zhang H; Su J; Zhou Q; Yang XN; Guo WB; Yan HH; Liu YH; Yan LX; Huang B; Zheng MM; Wu YL
Ann Oncol; 2018 Apr; 29(4):945-952. PubMed ID: 29346604
[TBL] [Abstract][Full Text] [Related]
3. Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases.
Ying S; Ke H; Ding Y; Liu Y; Tang X; Yang D; Li M; Liu J; Yu B; Xiang J; Mao X; Han-Zhang H; Hu W; Chen L
Cancer Biol Ther; 2019; 20(4):562-570. PubMed ID: 30395779
[TBL] [Abstract][Full Text] [Related]
4. Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC.
Zheng MM; Li YS; Jiang BY; Tu HY; Tang WF; Yang JJ; Zhang XC; Ye JY; Yan HH; Su J; Zhou Q; Zhong WZ; Yang XN; Guo WB; Chuai S; Zhang Z; Chen HJ; Wang Z; Liu C; Wu YL
J Thorac Oncol; 2019 May; 14(5):924-932. PubMed ID: 30659989
[TBL] [Abstract][Full Text] [Related]
5. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
6. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
[TBL] [Abstract][Full Text] [Related]
7. EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.
Zhao J; Ye X; Xu Y; Chen M; Zhong W; Sun Y; Yang Z; Zhu G; Gu Y; Wang M
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1305-1310. PubMed ID: 27770237
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.
Sakata Y; Kawamura K; Shingu N; Ichikado K
Lung Cancer; 2016 Sep; 99():120-2. PubMed ID: 27565925
[TBL] [Abstract][Full Text] [Related]
9. Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases.
Song Y; Liu P; Huang Y; Guan Y; Han X; Shi Y
Curr Cancer Drug Targets; 2019; 19(8):666-673. PubMed ID: 30332963
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
[TBL] [Abstract][Full Text] [Related]
11. Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.
Li S; Ke L; Meng X; Zhou H; Zhang X; Wu H; Yu J; Zhang H
Recent Pat Anticancer Drug Discov; 2021; 16(1):108-116. PubMed ID: 33245275
[TBL] [Abstract][Full Text] [Related]
12. Analysis of intrapatient heterogeneity of circulating tumor cells at the single-cell level in the cerebrospinal fluid of a patient with metastatic gastric cancer.
Cho JH; Sim MH; Kim SY; Kim K; Lee T; Lee J; Kang WK; Kim ST
J Cancer Res Ther; 2021; 17(4):1047-1051. PubMed ID: 34528562
[TBL] [Abstract][Full Text] [Related]
13. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.
Jin Y; Shao Y; Shi X; Lou G; Zhang Y; Wu X; Tong X; Yu X
Oncotarget; 2016 Sep; 7(38):61755-61763. PubMed ID: 27528220
[TBL] [Abstract][Full Text] [Related]
14. [Different Gene Mutation Spectrum of the Paired CSF and Plasma Samples in Lung Adenocarcinoma with Leptomeningeal Metastases: the Liquid Biopsy Based on Circulating Tumor DNA].
Li H; Xie Y; Lin Y; Yu T; Yin Z
Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):646-654. PubMed ID: 32838487
[TBL] [Abstract][Full Text] [Related]
15. Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non-Small Cell Lung Cancer.
Fan Y; Zhu X; Xu Y; Lu X; Xu Y; Wang M; Xu H; Ding J; Ye X; Fang L; Huang Z; Gong L; Lu H; Mao W; Hu M
Clin Cancer Res; 2018 Jan; 24(1):209-216. PubMed ID: 29030356
[No Abstract] [Full Text] [Related]
16. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer.
He J; Tan W; Ma J
Future Oncol; 2017 Apr; 13(9):787-797. PubMed ID: 28073294
[TBL] [Abstract][Full Text] [Related]
18. Leptomeningeal metastases in non-small-cell lung cancer.
Cheng H; Perez-Soler R
Lancet Oncol; 2018 Jan; 19(1):e43-e55. PubMed ID: 29304362
[TBL] [Abstract][Full Text] [Related]
19. Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.
Berger LA; Janning M; Velthaus JL; Ben-Batalla I; Schatz S; Falk M; Iglauer P; Simon R; Cao R; Forcato C; Manaresi N; Bramlett K; Buson G; Hanssen A; Tiemann M; Sauter G; Bokemeyer C; Riethdorf S; Reck M; Pantel K; Wikman H; Loges S
J Thorac Oncol; 2018 Dec; 13(12):e243-e246. PubMed ID: 30205165
[No Abstract] [Full Text] [Related]
20. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
